INTRODUCTION
Type 1 diabetes mellitus (T1DM) is characterized by an absolute deficiency of insulin and the treatment of choice is the substitution of exogenous insulin [1] . The optimal treatment model is an intensive insulin therapy attempting to reflect the physiological secretion of insulin [2] . The most important clinical issue in T1DM still remains chronic neurovascular complications of the disease. Lipid disorders are one of their risk factors. Thus, it seems important to pay attention to lipid abnormalities in T1DM in order to improve the prognosis and life expectancy in this group.
The lipid disorders in newly diagnosed T1DM arise from insulin deficiency, leading to increased lipolysis and metabolic decompensation. Patients in an insulin deficient state show reduced high-density lipoprotein cholesterol (HDL-C) and increased triglycerides (TG) levels.
The beneficial effect of insulin administered subcutaneously on lipid profile including improvement of HDL-C levels has been previously shown [3] [4] [5] . The pathophysiology of lipid abnormalities is not fully explained, but hyperinsulinemia resulting from the subcutaneous route of insulin administration is likely to play a role. Thus, patients with T1DM are characterized by significantly higher HDL-C level than healthy population [6] . Generally HDL-C is assumed to have beneficial impact, especially the anti-atherosclerotic function [7] .
However, it still remains unexplained whether HDL-C increase is associated with favorable prognosis of people with T1DM. Moreover, there are data about the relationship of extremely high HDL-C with higher risk of macroangiopathy in this group [8] . Finally, in T1DM, life expectancy is still shorter than their healthy counterparts [9] [10] , and the main reason for premature death in this group are cardiovascular diseases [11] .
The intensive insulin therapy is the recommended way of treatment due to proven protection against chronic complications [12] . In this method, which tries to mimic physiology, two types of insulin are used: NPH (Neutral Protamine Hagedorn) insulin or long-acting insulin analogs (so-called basal insulin) and rapid-acting analogs (used before main meals) with insulin pen devices or only rapid-acting analogs, when the personal insulin pump is used. It is necessary to adjust the dosage of insulin for optimum metabolic control and actual requirement and to do it from the onset of the disease [13] [14] [15] . There was no previous study describing prospectively, how initiation of insulin therapy at the onset of T1DM, affects the lipoprotein parameters.
This study aimed to investigate the influence of subcutaneous insulin therapy initiation on quantitative changes of HDL-C level and other components of lipid profile, in patients with newly diagnosed T1DM during a 1 year follow-up.
PATIENTS AND METHODS

Study design
Insulin Therapy and Lipoproteins Profile in Type 1 Diabetes Study (InLipoDiab1) is a prospective, observational study. Inclusion criteria to the study were: age between 18 and 35 years old, newly diagnosed T1DM without comorbidities and medications due to other causes, initiation of insulin treatment. Autoimmunology was confirmed by the positive specific autoantibodies: islet cell antibodies (a-ICA), glutamic acid decarboxylase antibodies (a-GAD) and tyrosine phosphatase antibodies (a-IA2). The study is registered at ClinicalTrials.gov (NCT02306005). All patients gave written informed consent to participate in the study. The study was carried out in accordance with the Declaration of Helsinki and approved by the local Ethics Committee (reference no.: 688/15).
All of the patients were hospitalized on average 5 days due to newly diagnosed T1DM in the Department of Internal Medicine and Diabetology. The patients were treated with intensive insulin therapy using insulin pens from the moment of diagnosis and underwent the same educational program conducted by specially trained nurse educator, diabetologist, psychologist and dietician. Intensive insulin therapy is defined as a treatment method requiring multiple daily insulin injections with adapting rapid-acting insulin doses before main meals, taking into account glucose level, desired carbohydrate intake, and considering upcoming physical activity. All participants of this study declared three main meals and one or two snacks, and they had injections of rapid-acting analog before each meal, and one or two injections of basal insulin (NPH or long-acting analog). After entering into a partial clinical remission, basically there was no need to provide basal insulin and the rapid-acting insulin analog converter was reduced to the amount of carbohydrates consumed [16, 17] .
The evaluation of the lipid profile was conducted at three-time points: at the time of diagnosis, before administration of insulin (baseline; Visit 0) and, at follow up after 3 months (Visit 1) and after one year of insulin treatment (Visit 2). The diagram of the design of the study is presented in the Figure 1 . For a reliable assessment of the effects of insulin therapy on lipoproteins level, it was extremely important to get the first blood samples of the patients at the time of the diagnosis, before the first doses of insulin. In a special questionnaire, patients supplied information about personal data and insulin dosing.
Laboratory tests
Serum concentration of HDL-C, total cholesterol (TC) and TG levels were measured with the Cobas 6000 biochemistry analyzer (Roche Diagnostics) using enzymatic colorimetric methods. Low-density lipoprotein cholesterol (LDL-C) level was calculated by the Friedewald formula [18] . Triglyceride/HDL-C ratio was calculated from the standard lipid profile by dividing TG by HDL-C using values in units of mg/dl. The non-HDL-C level was calculated by the formula: non-HDL-C = TC -HDL-C. Glycated hemoglobin (HbA1c) was assessed by a turbidimetric inhibition immunoassay (Cobas 6000 analyzer, Roche Diagnostics). C-peptide levels were measured by electrochemiluminescence immunoassay (Cobas 6000 analyzer, Roche Diagnostics). The measurement of HbA1c value was made in whole blood whereas all other measurements were performed in serum. Mean fasting glucose (MFG) and mean postprandial glucose (MPG) were measured using a capillary plasma with the glucometer. MPG was measured three times, 2 hours after major meals during the day.
MFG and MPG at discharge from the hospital were expressed as a mean of patients` measurements from all days of hospital stay whereas MFG and MPG at follow-up as a mean of patients' measurements on several days before visiting an outpatient clinic.
Insulin requirement
The daily dose of insulin (DDI) was defined as the requirement for insulin per kilogram of body weight per day. DDI was calculated as the amount of short and long-acting insulin (basal+bolus) at discharge from hospital and at follow-up visits in the outpatient clinic from the doses of insulin noted by the patients in their self-monitoring of blood glucose logs one day before the visit.
Statistical analysis
The statistical analysis was performed using the STATISTICA 13.0 program. The normality of data distributions was tested using Kolmogorov-Smirnov's test with Lillefors correction. The parameters were not normally distributed. All data were expressed as median values and interquartile range (IQR) and as numbers (percentage) of subjects. Data at onset and at 3 months and 12 months follow up were compared by ANOVA (Friedman test). The Wilcoxon test was used for comparison of changes in HDL-C between 3 and 12 months.
Patients were divided according to sex. Statistical significance was established at a P value of less than 0.05.
RESULTS
Patients
The study population consisted of 127 adults with newly diagnosed T1DM (86 men, 41 women). The median age of study group was 28 (24-33) years. 19% patients presented diabetic ketoacidosis at diagnosis, which has been identified in accordance with the recommendations of Diabetes Poland [19] . 82% of patients had preserved insulin reserve (Cpeptide concentration above 0.5 ng/ml) after 12 months of therapy indicating the prolonged partial remission.
Lipoproteins level changes
Changes in lipoproteins level during a 12 month observation are presented in Table 1 .
During the first year of insulin therapy, a significant increase in HDL-C was observed after 3 and 12 months of insulin therapy, and its values at these points were at a much higher level than the accepted norms for people with diabetes. In addition, the increase in HDL-C level, which appeared after 3 months, proceeded further in time (3 vs 12 months; p=0.004).
However, taking into account the division with respect to sex, this phenomenon was observed only in men (3 vs 12 months; p=0.02). The increase in HDL-C concentration (delta HDL-C) between control points is shown in Figure 2 . Regarding other lipid parameters, there was a significant decrease in TG and triglyceride/HDL-C ratio during the first year of insulin therapy. There was also a decrease in LDL-C and non-HDL-C concentration in the whole group, but the analysis with division into sex showed a decrease in concentration only in men.
A significant increase in TC was observed only in women.
DISCUSSION
The prospective observation revealed significant changes in lipid profile during 12 months of exogenous insulin therapy. What is interesting, the increase in HDL-C level appeared after 3 months of insulin therapy and persisted on the same elevated level after 12 months in women. However, in the whole group and men, this increase continued up to 12 months of treatment. The presented results are exceptional and this is the first observation with such a long follow-up. We can hypothesize that treatment with exogenous insulin changes lipid profile in a highly favorable way. We also observed significant changes in serum TG concentration in a similar pattern -first changes after 3 months, but in all patients, its concentration persisted on the same elevated level until to 12 months. It is well known that insulin deficiency promotes TG increase. Surprisingly, in our patients, median TG level remained normal at the time of diagnosis and during observation, and despite that, we observed a significant decrease in serum TG level.
In the literature there are some data about lipid profile in T1DM. In Guy et al. nonprospective study, lipid parameters values in youth with a brief history of T1DM (several years) were evaluated in a single measurement. Authors compared patients with T1DM with poor and good metabolic control and healthy. They showed that both groups of patients, with optimal and suboptimal metabolic control (with lower and higher insulin requirement), were characterized by higher levels of HDL-C versus the control group. Whereas the only group with good metabolic control and lower insulin requirement had a lower value of TG and triglyceride/HDL-C ratio versus control [4] . Moreover, in patients with higher DDI an increase in the concentration of total cholesterol, LDL-C and non-HDL-C has been observed.
Wilson et al. revealed that intensification of insulin delivery raises HDL-C levels after 3 and 6 months of treatment without significant changes in other levels of lipoprotein. This study was conducted on a relatively small study group consisting of young patients with T1DM and in a short period [3] . The authors found an increase in HDL-C levels after 3 months of observation, similarly to our previous observation [20] . Sinha et al. compared lipid parameters in patients with newly diagnosed T1DM and in patients with type 2 diabetes mellitus after unsuccessful oral hypoglycemic treatment. Both groups of patients received similar insulin doses, but improvement in all parameters of lipid profile was present only in patients with T1DM. This study is limited to a short, 6-month follow-up and a small number of patients, especially with newly diagnosed T1DM (only 9 patients) [5] . Fukui et al. showed that patients with T1DM and type 2 diabetes mellitus treated with insulin presented higher HDL-C values in comparison with type 2 diabetes mellitus patients without insulin. However, the highest concentration of HDL-C was in patients with T1DM. These patients also had a higher total dose of injected insulin compared with patients with type 2 diabetes mellitus [21] . Thus, all above-mentioned studies were of short duration with the small number of patients with T1DM and none of them were prospective. To confirm and describe the beneficial effect of exogenous insulin on HDL-C it is important to have the observation over an extended period of time.
Among non-pharmacological methods which increase HDL-C level are smoking cessation, physical activity and diet modification. It has been shown that smokers are prone to have lower HDL-C levels compared to non-smokers [22] . Moreover, smoking cessation contributes to increased HDL-C level [23] . The dietary intervention improves the lipid profile [24] . There are many components of the diet with proven effectiveness in raising the concentration of HDL-C level [25] [26] . HDL-C level can also be increased naturally with regular physical activity [27] . Therefore, in order to assess the changes in HDL-C level, it is important to take into account the natural factors influencing it. Our patients had a balanced diet in accordance with recommendation of Diabetes Poland. Some of our patients improved their lifestyle by quitting smoking (12% of patients) and starting physical activity (24% of patients). Because it has been shown that physical activity and smoking cessation improve HDL-C level by only 5-10% [28] , we assumed that these steps had a small effect on HDL-C increase.
One of the actions of insulin is to decrease the very low-density lipoprotein (VLDL) level. The deficiency of insulin results in increasing VLDL level and promotes the production of LDL-C. Insulin reduces VLDL production by diminishing circulating free fatty acids, which are substrates for VLDL and by a direct inhibitory effect in the hepatocyte. Insulin is an activator of lipoprotein lipase consequently leading to reducing plasma triglyceride level. In our study group, a significant decrease in LDL-C concentration during 12 months of followup was observed.
Also, our study shows that exogenous insulin treatment influences the lipid profile by reducing the value of two clinically relevant parameters: triglyceride/HDL-C ratio and non-HDL-C level. An increase in the values of these parameters is combined with higher risk of the development of vascular complications among patients with T1DM [29] [30] .
Triglyceride/HDL-C ratio and non-HDL-C have a proven relationship with cardiovascular disease, insulin resistance, and type 2 diabetes mellitus. Non-HDL-C is one of the criteria for metabolic control of T1DM. However, in the case of people with T1DM, caution should be exercised in interpreting the results of non-HDL-C concentration, because its value is due to the concentration of HDL-C. In this case, elevated HDL-C levels distort the non-HDL-C concentration, leading to a misinterpretation of its value. There are no studies assessing the prospective impact of triglyceride/HDL-C ratio and non-HDL-C on the development of cardiovascular disease and survival in T1DM. 
